Identification of pyrrolo[2,3-d]pyrimidine-based dual MERTK and FLT3 inhibitor: Hit-to-lead, machine learning, modeling, synthesis, and biological evaluation

European Journal of Pharmaceutical Sciences 2026 Open access

Read full text
Authors: Abdellah Yamani, Paweł Maliszewski, Natalia Piórkowska, Patrycja Olejkowska-Podgórska, Wojciech Pietruś, Mario Luigi Naitana, Agata Mitkowska, Artur Łaszek, Delfina Popiel, Agata Mikołajczyk, Tomasz Kornatowski, Kinga Jastrzębska
+12 more Filip Mituła, Jakub Dominowski, Artur Janusz, Michał Górka, Joanna Hucz-Kalitowska, Małgorzata Teska-Kamińska, Aleksandra M. Stanczak, Monika Delis, Damian A. Smuga, Jerzy Pieczykolan, KRZYSZTOF K. DUBIEL, Maciej Wieczorek
DOI: 10.1016/j.ejps.2025.107421
Cited by: 1
References: 67

Abstract

value of 7.50 nM). Furthermore, compound 31l displayed a favorable metabolic stability profile in both human and mouse liver microsome screens and an oral bioavailability of 56%. This finding suggests that lead compound 31l is a promising tool for further optimization and development as a potential MERTK/FLT3 dual inhibitor anti-AML drug candidate.

Fields of Study & Subjects

Phagocytosis and Immune Regulation Microtubule and mitosis dynamics Cellular transport and secretion

Publication details

Journal / source
European Journal of Pharmaceutical Sciences
Publisher
Elsevier BV
Volume
219
Pages
107421–107421
Publication date
30 January 2026
Language
EN